BioNTech SE licences Cresendo Bios Humabody technology
BioNTech and Crescendo Biologics have signed a US-$790m deal to develop multi-specific precision immunotherapies .
Novartis AG executes licence option with Molecular Partners
After Molecular Partners AG reported an 78% reduction of hospitalisation by a single ensovibep dose in infected COVID-19 patients, Novartis AG is to pay a CHF150m milestone.
Neurimmune inks US-$760 deal with AstraZeneca
Neurimmune has entered into a collaboration and license agreement with AstraZeneca subsidiary Alexion Pharmaceuticals to commercialise its antibody NI006.
Santhera finds Chinese marketing partner for vamorolone
Swiss Santhera Pharmaceuticals has entered into a $124m licence deal with Chinese Sperogenix Therapeuticis to market its DMD drug vamorolone.
DNA Script bags US$200m financing
Moderna’s US-French partner DNA Script has raised additional $35m as a second tranche of a Series C financing to advance its Enzymatic DNA Synthesis platform, Syntax.
Sound Bioventures Fund I AB closes at 110m
Novo Holdings, together with Saminvest, Vækstfonden, the European Investment Fund and its three co-founders have put 110m in the first fund of Sound Bioventures AB.
Omicron variant more harmless than Delta
The new year begins with good news.
Season Greetings
Merry Christmas and a Happy New Year!
Novo Holdings invests 86m in 21st.BIO
Novo Holdings is set to invest 86m in 21st.BIO A/S a new Danish bioindustrial scale-up company to boost the production of proteins.
Novartis AG snags Gyroscope for US$1.5bn
Ocular gene therapy specialist Gyroscope Therapeutics Holdings plc is to be acquired by Novartis AG for up to $1.5bn.